GENMAB

Genmab said Monday it is raising $6 billion in debt through a combination of notes and loans to help fund its pending acquisition of biotechnology company Merus.

Genmab A/S on Tuesday said it has commenced a cash tender offer to acquire all outstanding shares of Merus N.V. for $97.00 per share, formally launching its approximately $8 billion acquisition of the biotechnology company.

Genmab A/S said Saturday that updated data from a mid-stage trial showed its experimental drug, rinatabart sesutecan, demonstrated sustained anti-tumor activity in patients with advanced endometrial cancer.

Global sales of Genmab's cancer drug Darzalex rose to $3.67 billion in the third quarter, a 22% increase from the same period a year earlier, according to a company announcement on Tuesday.

Danish biotechnology company Genmab A/S said Monday it agreed to acquire Merus N.V. in an all-cash deal valued at approximately $8.0 billion, its largest acquisition to date.